Daniel V T Catenacci Selected Research

Daniel V T Catenacci Research Topics

Disease

41	Neoplasms (Cancer) 12/2022 - 08/2009
24	Adenocarcinoma 12/2022 - 01/2013
11	Stomach Neoplasms (Stomach Cancer) 12/2022 - 12/2011
3	Neutropenia 11/2022 - 11/2017
3	Neoplasm Metastasis (Metastasis) 01/2022 - 05/2015
2	Disease Progression 11/2021 - 11/2017
2	Cholangiocarcinoma 11/2021 - 03/2014
2	Microsatellite Instability 12/2019 - 11/2019
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2019 - 12/2015
1	Pneumonia (Pneumonitis) 11/2022
1	Stomatitis 11/2022
1	Sepsis (Septicemia) 11/2022
1	Duodenitis 01/2022
1	Fever (Fevers) 01/2022
1	Hyperthyroidism 01/2022
1	Residual Neoplasm 12/2021
1	Esophageal Neoplasms (Esophageal Cancer) 11/2021
1	Ascites 11/2021
1	Inflammation (Inflammations) 01/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2020
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2020
1	Nausea 01/2020
1	Anemia 01/2020
1	Vomiting 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2019
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2019
1	Fatigue 11/2017

Drug/Important Bio-Agent (IBA)

9	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2011
5	Circulating Tumor DNAIBA 12/2022 - 01/2018
5	Trastuzumab (Herceptin)FDA Link 01/2020 - 10/2016
5	Proteins (Proteins, Gene)FDA Link 01/2017 - 01/2013
4	Fluorouracil (Carac)FDA LinkGeneric 11/2022 - 01/2019
4	Monoclonal AntibodiesIBA 11/2022 - 12/2011
4	Leucovorin (Folinic Acid)FDA Link 11/2022 - 01/2019
4	Irinotecan (Camptosar)FDA LinkGeneric 12/2021 - 01/2019
4	DNA (Deoxyribonucleic Acid)IBA 12/2019 - 03/2014
3	GSK 1363089IBA 01/2022 - 01/2013
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2019 - 12/2011
3	LigandsIBA 11/2017 - 12/2011
2	Nucleic AcidsIBA 12/2022 - 01/2022
2	DeoxyriboseIBA 12/2022 - 01/2022
2	pembrolizumabIBA 11/2022 - 01/2020
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 11/2022 - 01/2019
2	bemarituzumabIBA 11/2022 - 01/2020
2	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 11/2022 - 01/2020
2	Cell-Free Nucleic AcidsIBA 01/2022 - 12/2019
2	folfirinoxIBA 12/2021 - 01/2019
2	Immune Checkpoint InhibitorsIBA 11/2021 - 12/2020
2	pegfilgrastim (Neulasta)FDA Link 01/2020 - 01/2019
2	Phosphotransferases (Kinase)IBA 11/2019 - 01/2019
2	tyrosine receptor (receptor, tyrosine)IBA 11/2019 - 01/2019
2	onartuzumabIBA 03/2014 - 12/2011
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2013 - 12/2011
1	epacadostatIBA 11/2022
1	Protein Isoforms (Isoforms)IBA 11/2022
1	Immunoglobulin G (IgG)IBA 11/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	cyclopropapyrroloindoleIBA 01/2022
1	IpilimumabIBA 01/2022
1	NivolumabIBA 01/2022
1	Transaminases (Aminotransferases)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Tumor Biomarkers (Tumor Markers)IBA 01/2022
1	VaccinesIBA 01/2022
1	Trinitrotoluene (TNT)IBA 12/2021
1	ivosidenibIBA 11/2021
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 11/2021
1	Docetaxel (Taxotere)FDA Link 04/2021
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 03/2021
1	atezolizumabIBA 01/2021
1	AntibodiesIBA 01/2021
1	B7-H1 AntigenIBA 12/2020
1	Alkaline PhosphataseIBA 01/2020
1	tremelimumabIBA 01/2020
1	130-nm albumin-bound paclitaxelIBA 01/2020
1	AntralIBA 01/2020
1	margetuximabIBA 01/2020
1	durvalumabIBA 01/2020
1	AMG 337IBA 04/2019
1	AfatinibIBA 01/2019
1	RamucirumabIBA 01/2019
1	PlatinumIBA 01/2019
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2019
1	rilotumumabIBA 11/2017
1	Capecitabine (Xeloda)FDA Link 11/2017
1	Epirubicin (Ellence)FDA LinkGeneric 11/2017
1	Cisplatin (Platino)FDA LinkGeneric 11/2017
1	methionylmethionine (Met-Met)IBA 01/2017

Therapy/Procedure

26	Therapeutics 12/2022 - 04/2011
11	Drug Therapy (Chemotherapy) 12/2022 - 09/2013
3	Neoadjuvant Therapy 12/2021 - 01/2021
2	Immunotherapy 11/2022 - 12/2019
2	Precision Medicine 01/2021 - 08/2009
1	Induction Chemotherapy 01/2022
1	Chemoradiotherapy 12/2021
1	Cytoreduction Surgical Procedures 08/2021
1	Metastasectomy 08/2021
1	Gastrectomy 08/2021
1	Adjuvant Chemotherapy 04/2021
1	Hyperthermic Intraperitoneal Chemotherapy 03/2021